AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17627809 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdomino-perineal resection (APR)
Number of subjects: 884
Study 17627809 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of examined lymph nodes (LN)
Number of subjects: 884
Study 15591332 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 30
Study 15591332 — intervention group
Group type: COMPARATOR
Intervention: Standard Laryngeal Mask Airway (SLMA)
Number of subjects: 30
Study 14624914 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg OD
Number of subjects: 49
Study 14624914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10890377 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum S-100beta levels
Number of subjects: 50
Study 10890377 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) levels
Number of subjects: 50
Study 10890377 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (IL-10) levels
Number of subjects: 50
Study 10890377 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-12 (IL-12) levels
Number of subjects: 50
Study 10890377 — intervention group
Group type: EXPERIMENTAL
Intervention: S-100beta level
Number of subjects: 50
Study 10890377 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic profile
Number of subjects: 50
Study 10890377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment IL levels
Number of subjects: 50
Study 8859063 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate sodium
Number of subjects: 0
Study 8859063 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 8859063 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study 1514348 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1
Number of subjects: 64
Study 1514348 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 64
Study 6397516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin synthesis inhibition by indomethacin (150 mg daily for three days plus an additional 50 mg on the morning of the active experiments)
Number of subjects: 10
Study 6397516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin synthesis inhibition by indomethacin
Number of subjects: 10
Study 31076882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal septal retainer
Number of subjects: 39
Study 31076882 — intervention group
Group type: COMPARATOR
Intervention: Merocel nasal packing
Number of subjects: 39
Study 30207513 — intervention group
Group type: EXPERIMENTAL
Intervention: All-families component via school- and community-based intervention
Number of subjects: 30209
Study 30207513 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk families component with seven counselling sessions and text-messaging intervention
Number of subjects: 30209
Study 26572899 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg (1 capsule 1 hour before surgery and 1 placebo capsule every 8 hours for 2 days)
Number of subjects: 34
Study 26572899 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 10 mg (1 capsule 1 hour before surgery and every 8 hours for 2 days)
Number of subjects: 34
Study 25247991 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month maintenance program consisting of one monthly supervised high intensity interval training session, a written exercise program and exercise diary, and a maximum exercise test every third month during follow-up.
Number of subjects: 49
Study 25247991 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study 25247991 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month maintenance program
Number of subjects: 49
Study 22310086 — intervention group
Group type: EXPERIMENTAL
Intervention: PF tafluprost 0.0015%
Number of subjects: 643
Study 22310086 — intervention group
Group type: COMPARATOR
Intervention: PF timolol 0.5%
Number of subjects: 643
Study 20103758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy with hydrocortisone
Number of subjects: 509
Study 20103758 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy with hydrocortisone
Number of subjects: 509
Study 20103758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone with intensive insulin therapy
Number of subjects: 509
Study 20103758 — intervention group
Group type: COMPARATOR
Intervention: Fludrocortisone with conventional insulin therapy
Number of subjects: 509
Study 18049323 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions for siblings of hospitalized children, conducted by child life specialists, focusing on hospitalization, illness or injury, and treatment.
Number of subjects: 50
Study 18049323 — intervention group
Group type: COMPARATOR
Intervention: No educational interventions (Control group)
Number of subjects: 50
Study 16079312 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Number of subjects: 0
Study 16079312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12099653 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted follow-up (intensive and low-intensity)
Number of subjects: 358
Study 12099653 — intervention group
Group type: COMPARATOR
Intervention: Minimal surveillance
Number of subjects: 358
Study 12099653 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted follow-up (high risk)
Number of subjects: 358
Study 12099653 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted follow-up (high and low risk)
Number of subjects: 358
Study 9509976 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim) 5 microg/kg/day starting on day +1 until ANC > 500/microl
Number of subjects: 40
Study 9509976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G‐CSF)
Number of subjects: 40
Study 9509976 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim)
Number of subjects: 40
Study 8092777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin E2 gel (1 mg of dinoprostone/2.5 ml gel)
Number of subjects: 60
Study 8092777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 gel (0.5 mg of dinoprostone in 2.5 ml of two different vehicles)
Number of subjects: 60
Study 8092777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin gel alone
Number of subjects: 60
Study 8092777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin pre-induction
Number of subjects: 60
Study 3402178 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin sodium 100 units/mL flush solution
Number of subjects: 160
Study 3402178 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride flush solution
Number of subjects: 160
Study 31138733 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 451
Study 31138733 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 451
Study 31138733 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects across BMI strata
Number of subjects: 451
Study 31138733 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 451
Study 30142141 — intervention group
Group type: EXPERIMENTAL
Intervention: History of Intimate Partner Violence (IPV) in the past 12 months
Number of subjects: 964
Study 30142141 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in HIV-related care
Number of subjects: 964
Study 30142141 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of Antiretroviral Therapy (ART)
Number of subjects: 964
Study 30142141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds of engagement in care for those with IPV
Number of subjects: 964
Study 30142141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds of ART initiation for those with IPV
Number of subjects: 964
Study 27373530 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Number of subjects: 23
Study 27373530 — intervention group
Group type: COMPARATOR
Intervention: Light intensity control
Number of subjects: 23
Study 24691032 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR exercise with rapamycin (RAP) 16 mg administered 1 h prior to exercise
Number of subjects: 16
Study 24691032 — intervention group
Group type: COMPARATOR
Intervention: BFR exercise (Control group, CON)
Number of subjects: 16
Study 22111758 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 mm diameter implants (test group)
Number of subjects: 12
Study 22111758 — intervention group
Group type: COMPARATOR
Intervention: 4.3 mm diameter implants (control group)
Number of subjects: 12
Study 19809412 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily (group A)
Number of subjects: 73
Study 19809412 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily (group B)
Number of subjects: 73
Study 19809412 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg every other day (group C)
Number of subjects: 73
Study 19809412 — intervention group
Group type: COMPARATOR
Intervention: Patients not receiving PPI
Number of subjects: 73
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific drugs not mentioned)
Number of subjects: 0
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based regimens (specific regimens not mentioned)
Number of subjects: 0
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (dosage not specified)
Number of subjects: 0
Study 18265809 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study 18265809 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum based regimens
Number of subjects: 0
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy
Number of subjects: 0
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy (specific drugs not mentioned)
Number of subjects: 0
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for patients with brain metastases
Number of subjects: 0
Study 18265809 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific drugs for patients with bone metastases
Number of subjects: 0
Study 15794038 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite adhesive with 37% phosphoric acid etch
Number of subjects: 60
Study 15794038 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite adhesive after microetching, hydrofluoric acid, and silane
Number of subjects: 60
Study 15794038 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite adhesive with acid-etch primer
Number of subjects: 60
Study 15794038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate adhesive with 35% phosphoric acid etch
Number of subjects: 60
Study 12221220 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy + micronutrients (E + M)
Number of subjects: 75
Study 12221220 — intervention group
Group type: COMPARATOR
Intervention: Micronutrients (M)
Number of subjects: 75
Study 9674677 — intervention group
Group type: EXPERIMENTAL
Intervention: 016 x 022 inch active martensitic medium force nickel titanium
Number of subjects: 56
Study 9674677 — intervention group
Group type: EXPERIMENTAL
Intervention: 016 x 022 inch graded force active martensitic nickel titanium
Number of subjects: 56
Study 9674677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0155 inch multistrand stainless steel
Number of subjects: 56
Study 7860155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene education intervention (not detailed in the abstract)
Number of subjects: 1914
Study 2687194 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol
Number of subjects: 81
Study 2687194 — intervention group
Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 81
Study 1214706 — intervention group
Group type: EXPERIMENTAL
Intervention: Alice strain vaccine (AS) intranasally
Number of subjects: 191
Study 1214706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 7012470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfosal (1 gram three times a day for eight days)
Number of subjects: 60
Study 7012470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31806172 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic mediation device by singing
Number of subjects: 0
Study 31806172 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 27218605 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 116
Study 25504268 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieve 15‐mm catheter (group 1, 15 patients)
Number of subjects: 30
Study 25504268 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieve 20 mm (group 2, 15 patients)
Number of subjects: 30
Study 25504268 — intervention group
Group type: COMPARATOR
Intervention: Standard circular mapping catheter (SCMC)
Number of subjects: 30
Study 23660095 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-infection therapy within 1 hour after admission (Observation group)
Number of subjects: 80
Study 23660095 — intervention group
Group type: COMPARATOR
Intervention: Anti-infection therapy 1-6 hours after admission (Control group)
Number of subjects: 80
Study 22098179 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based and print materials for food safety education
Number of subjects: 0
Study 22098179 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19191091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day)
Number of subjects: 127
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐II receptor blockers (ARBs)
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme (ACE) inhibitors
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐channel blockers (CCBs)
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐blockers
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (a type of CCB)
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: ARBs
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 347
Study 18200818 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBs
Number of subjects: 347
Study 15109470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretravel brochures explaining the hazards of drug abuse
Number of subjects: 1000
Study 15109470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brochures)
Number of subjects: 1000
Study 15109470 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall drug use
Number of subjects: 1000
Study 11687449 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose (10 microg of PRP antigen)
Number of subjects: 600
Study 11687449 — intervention group
Group type: EXPERIMENTAL
Intervention: One-half dose (5.0 microg of PRP antigen)
Number of subjects: 600
Study 11687449 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third dose (3.3 microg of PRP antigen)
Number of subjects: 600
Study 9744695 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole infusion
Number of subjects: 508
Study 9744695 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)/non‐steroidal anti‐inflammatory drug (NSAID) intake before admission
Number of subjects: 508
Study 9744695 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric ulcer localization
Number of subjects: 508
Study 9744695 — intervention group
Group type: COMPARATOR
Intervention: Greater age
Number of subjects: 508
Study 9744695 — intervention group
Group type: COMPARATOR
Intervention: Shock
Number of subjects: 508
Study 9744695 — intervention group
Group type: COMPARATOR
Intervention: Heart disease
Number of subjects: 508
Study 9744695 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure < 100 mmHg at admission
Number of subjects: 508
Study 9744695 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous ulcer history
Number of subjects: 508
Study 9744695 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a Forrest class IIa ulcer
Number of subjects: 508
Study 7920019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine 0.1% eye drops, one drop in each eye t.i.d. for 4 weeks
Number of subjects: 30
Study 7920019 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops, one drop in each eye t.i.d. for 4 weeks
Number of subjects: 30
Study 3337783 — intervention group
Group type: EXPERIMENTAL
Intervention: New nasopharyngeal airway with introducer
Number of subjects: 0
Study 3337783 — intervention group
Group type: COMPARATOR
Intervention: Standard red rubber airway
Number of subjects: 0
Study 31148509 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided positioning system
Number of subjects: 100
Study 31148509 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 100
Study 30830937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder (BD) group
Number of subjects: 580
Study 30830937 — intervention group
Group type: COMPARATOR
Intervention: Control group (stroke patients without BD)
Number of subjects: 580
Study 29223430 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide withdrawal
Number of subjects: 220
Study 29223430 — intervention group
Group type: COMPARATOR
Intervention: Furosemide maintenance
Number of subjects: 220
Study 26386123 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib/BSC (5 mg twice-daily)
Number of subjects: 202
Study 26386123 — intervention group
Group type: COMPARATOR
Intervention: Placebo/BSC
Number of subjects: 202
Study 26386123 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib/BSC
Number of subjects: 202
Study 23354535 — intervention group
Group type: EXPERIMENTAL
Intervention: B. monniera (Brahmi) extract 450 mg
Number of subjects: 72
Study 23354535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 22214254 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (400 mg daily, 100 mg per tablet, two tablets twice daily)
Number of subjects: 98
Study 22214254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tasting chewable tablets)
Number of subjects: 98
Study 22214254 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (400 mg daily)
Number of subjects: 98
Study 22214254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 19201576 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy (Bifidobacterium longum 2 x 10(9) CFU daily)
Number of subjects: 120
Study 19201576 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic therapy (8.0 g of psyllium daily)
Number of subjects: 120
Study 19201576 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (both probiotic and prebiotic treatments)
Number of subjects: 120
Study 16788341 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiscal approach
Number of subjects: 30
Study 16788341 — intervention group
Group type: COMPARATOR
Intervention: Classic approach
Number of subjects: 30
Study 15884251 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/day of continuous transdermal estradiol with sequential transdermal norethisterone acetate (NETA) in daily doses of 170 micrograms in a single transdermal patch
Number of subjects: 75
Study 15884251 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study 10659551 — intervention group
Group type: COMPARATOR
Intervention: Original brand (Tylenol, Cilag)
Number of subjects: 10
Study 10659551 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation (Sara, Thai Nakorn Patana)
Number of subjects: 10
Study 8709381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 20
Study 8709381 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and cefazolin parenterally followed by cephradine orally
Number of subjects: 20
Study 1716790 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg BW i.v.)
Number of subjects: 4
Study 1716790 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg BW i.v.) + Dextran 70 (30 g i.v.)
Number of subjects: 4
Study 1716790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (30 g i.v.)
Number of subjects: 4
Study 1716790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6644348 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 X 10(6) U/m2 every other day for 2 weeks
Number of subjects: 9
Study 6644348 — intervention group
Group type: COMPARATOR
Intervention: 5 X 10(6) U/m2 weekly
Number of subjects: 9
Study 31795854 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of employment services based on the evidence‐based individualized placement and support model
Number of subjects: 2160
Study 30843758 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game
Number of subjects: 275
Study 30843758 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 275
Study 30843758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard game difficulty
Number of subjects: 275
Study 30843758 — intervention group
Group type: COMPARATOR
Intervention: Easy game difficulty
Number of subjects: 275
Study 30843758 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D:4D digit ratio
Number of subjects: 275
Study 29490577 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-whey-protein (22 g·L‐1) CE drink (CW‐M)
Number of subjects: 10
Study 29490577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-whey-protein (33 g·L‐1) CE drink (CW‐H)
Number of subjects: 10
Study 29490577 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate CE drink (CE‐H)
Number of subjects: 10
Study 29490577 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate CE drink (CE‐L)
Number of subjects: 10